Advanced Proteome Therapeutics Announces Warrant Extension
Advanced Proteome Therapeutics Announces Warrant Extension
Vancouver, British Columbia--(Newsfile Corp. - March 18, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") announces that, it has applied to the TSX Venture Exchange for approval to amend the expiration of certain outstanding warrants (the "Warrants"). The Warrants' exercise price and original expiry date are detailed below. The Warrants expiry date is to be extended to September 30, 2022. The warrants to be amended do not include any warrants issued to finders or agents. No other terms of the warrants are to be amended and the exercise remains at $0.27.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年3月18日)-高級蛋白質組治療公司(多倫多證券交易所：APC)(證券交易所：0E81)(“APC”或“公司”)宣佈，已向多倫多證券交易所創業板申請批准修訂若干尚未到期的認股權證(“認股權證“)。認股權證的行使價及原來的到期日詳列如下。認股權證的到期日將延展至2022年9月30日。將予修訂的認股權證不包括向尋獲人或代理人發行的任何認股權證。認股權證的其他條款不會修訂，行權金額維持在0.27美元。
| Original Exercise Price | Number Outstanding | Original Expiry Date |
| Warrants @ $0.27 | 3,091,000 | March 27, 2022 |
| Warrants @ $0.27 | 1,667,000 | April 5, 2022 |
| Warrants @ $0.27 | 2,559,073 | April 13, 2022 |
| 原行權價格 | 突出的數字 | 原到期日 |
| 認股權證@0.27美元 | 3,091,000 | 2022年3月27日 |
| 認股權證@0.27美元 | 1,667,000 | 2022年4月5日 |
| 認股權證@0.27美元 | 2,559,073 | 2022年4月13日 |
Holders of warrants will not receive an amended warrant certificate and will be required to submit their original warrant certificate in order to exercise warrants.
認股權證持有人將不會收到修改後的認股權證證書，並將被要求提交其原始認股權證證書以行使認股權證。
ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.
關於該公司：
高級蛋白質組治療公司通過其子公司高級蛋白質組治療公司發明了專有的蛋白質結合技術，通過改進的特定部位標記、藥物-抗體比率控制和組合有效載荷，能夠開發出卓越的抗體-藥物結合。這項技術具有令人信服的臨牀前數據，表明與當前最先進的連接體技術相比，改善了同質性並提高了體內效力。該公司相信，這項技術將使開發更安全、更有效的抗體-藥物結合療法成為可能，並正在尋求許可和合作機會，以推進開發並創造股東價值。
FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
Paul Woodward
President and CEO
Tel: 604 690-3797
欲瞭解更多信息，請聯繫：
高級蛋白質組治療公司
保羅·伍德沃德
總裁兼首席執行官
電話：604690-3797
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements.
本新聞稿中提及的證券沒有，也不會根據修訂後的1933年《美國證券法》進行註冊，如果沒有在美國註冊或沒有美國註冊要求的適用豁免，不得在美國境內或向美國人提供或出售，或為美國人的賬户或利益而提供或銷售。
This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.
本新聞稿不構成出售證券的要約，也不招攬購買任何證券的要約。在美國，任何公開發行證券都必須通過招股説明書的方式進行，招股説明書中包含公司和管理層的詳細信息，以及財務報表。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。